Novel serum tumor marker, RCAS1, in pancreatic diseases.

AIM As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors. RESULTS When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%). CONCLUSION These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.

[1]  T. Oshikiri,et al.  RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma , 2002, Annals of Surgical Oncology.

[2]  日本膵臓学会.  Classification of pancreatic carcinoma , 2003 .

[3]  T. Oshikiri,et al.  High expression of tumor‐associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker , 2002, International journal of cancer.

[4]  K. Kotoh,et al.  RCAS1 expression in immune-mediated liver diseases. , 2002, Journal of clinical gastroenterology.

[5]  T. Kazui,et al.  A highly polymorphic CA repeat marker at the EBAG9/RCAS1 locus on 8q23 that detected frequent multiplication in breast cancer , 2002, Annals of human biology.

[6]  T. Oshikiri,et al.  RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer , 2001, British Journal of Cancer.

[7]  S. Inoue,et al.  EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine–immune interactions , 2001, British Journal of Cancer.

[8]  H. Nawata,et al.  Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. , 2001, International journal of oncology.

[9]  K. Sugimachi,et al.  Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. , 2001, Cancer letters.

[10]  Y. Nakanishi,et al.  Expression of tumor‐associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma , 2001, Cancer.

[11]  K. Ohshima,et al.  Expression of human tumor‐associated antigen RCAS1 in Reed‐Sternberg cells in association with Epstein‐Barr virus infection: A potential mechanism of immune evasion , 2001, International journal of cancer.

[12]  Hidetoshi Takahashi,et al.  RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. , 2001, Journal of dermatological science.

[13]  H. Nawata,et al.  Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. , 2001, Blood.

[14]  T. Kaku,et al.  The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. , 2000, Gynecologic oncology.

[15]  M. Nakashima,et al.  Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 , 1999, Nature Medicine.

[16]  T. Kaku,et al.  The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Kaku,et al.  A novel tumor‐associated antigen expressed in human uterine and ovarian carcinomas , 1996, Cancer.